{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T14:01:52Z","timestamp":1776261712990,"version":"3.50.1"},"reference-count":47,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2019.11105","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T14:00:03Z","timestamp":1573826403000},"source":"Crossref","is-referenced-by-count":10,"title":["Current and future roles of biosimilars in oncology practice (Review)"],"prefix":"10.3892","author":[{"given":"Sofia","family":"Konstantinidou","sequence":"first","affiliation":[{"name":"Oncology Unit, The Third Department of Medicine, Medical School, National and Kapodistrian University of Athens, 115 27 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeliki","family":"Papaspiliou","sequence":"additional","affiliation":[{"name":"Oncology Unit, The Third Department of Medicine, Medical School, National and Kapodistrian University of Athens, 115 27 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Kokkotou","sequence":"additional","affiliation":[{"name":"Oncology Unit, The Third Department of Medicine, Medical School, National and Kapodistrian University of Athens, 115 27 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"key":"key20200714095815_b1-ol-0-0-11105","first-page":"22","article-title":"Biosimilars in oncology","volume":"12","author":"Zelenetz","year":"2016","journal-title":"Oncol Hematol Rev"},{"key":"key20200714095815_b2-ol-0-0-11105","first-page":"688","article-title":"Integrating biosimilars into oncology practice: Implications for the advanced practitioner","volume":"8","author":"Campen","year":"2017","journal-title":"J Adv Pract Oncol"},{"key":"key20200714095815_b3-ol-0-0-11105","article-title":"Ten things pharmacists should know about biologics and biosimilars","author":"Robinson","year":"2018","journal-title":"Pharmaceutical J"},{"key":"key20200714095815_b4-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"e000142","DOI":"10.1136\/esmoopen-2016-000142","article-title":"Biosimilars: A position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers","volume":"1","author":"Tabernero","year":"2017","journal-title":"ESMO Open"},{"key":"key20200714095815_b5-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1359-6349(13)70001-6","article-title":"Clinical consideration for biosimilar antibodies","volume":"11","author":"Mellstedt","year":"2013","journal-title":"EJC Suppl"},{"key":"key20200714095815_b6-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.2147\/CMAR.S164201","article-title":"The role of biosimilars in value-based oncology care","volume":"10","author":"Patel","year":"2018","journal-title":"Cancer Manag Res"},{"key":"key20200714095815_b7-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"e000180","DOI":"10.1136\/esmoopen-2017-000180","article-title":"Biologics and biosimilars: What, why and how?","volume":"2","author":"Chan","year":"2017","journal-title":"ESMO Open"},{"key":"key20200714095815_b8-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"161","DOI":"10.12998\/wjcc.v6.i8.161","article-title":"Biosimilars: Review of current applications, obstacles, and their future in medicine","volume":"6","author":"Kaida-Yip","year":"2018","journal-title":"World J Clin Cases"},{"key":"key20200714095815_b9-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"7s","DOI":"10.1200\/JOP.2017.026831","article-title":"Emerging opportunities and challenges of biosimilars in oncology practice","volume":"13","author":"Lyman","year":"2017","journal-title":"J Oncol Pract"},{"key":"key20200714095815_b10-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.2217\/fon-2018-0044","article-title":"Talking to patients about biosimilars","volume":"14","author":"Janjigian","year":"2018","journal-title":"Future Oncol"},{"key":"key20200714095815_b11-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1200\/JGO.2016.008607","article-title":"Improving access to cancer treatments: The role of biosimilars","volume":"3","author":"Chopra","year":"2017","journal-title":"J Glob Oncol"},{"key":"key20200714095815_b12-ol-0-0-11105","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918818335","article-title":"Academic oncology clinicians' understanding of biosimilars and information needed before prescribing","author":"Cook","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"key20200714095815_b13-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/imj.14033","article-title":"Biosimilars are coming: Ready or not","volume":"48","author":"Zalcberg","year":"2018","journal-title":"Intern Med J"},{"key":"key20200714095815_b14-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2217\/fon-2018-0680","article-title":"Demystifying biosimilars: Development, regulation and clinical use","volume":"15","author":"Rugo","year":"2019","journal-title":"Future Oncol"},{"key":"key20200714095815_b15-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2217\/fon-2017-0157","article-title":"Preparing for a new generation of biologic therapies: Understanding the development and potential of biosimilar cancer therapeutics","volume":"13","author":"Coiffier","year":"2017","journal-title":"Future Oncol"},{"key":"key20200714095815_b16-ol-0-0-11105","first-page":"1","article-title":"From bioequivalence to biosi.milarity: The rise of a novel regulatory framework","volume":"66","author":"Karalis","year":"2016","journal-title":"Drug Res (Stuttg)"},{"key":"key20200714095815_b17-ol-0-0-11105","article-title":"How the U.S. Compares to Europe on Biosimilar Approvals and Products in the Pipeline","author":"Harston","year":"2019"},{"key":"key20200714095815_b18-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.clinthera.2018.03.018","article-title":"Monoclonal antibody biosimilars in oncology: Critical appraisal of available data on switching","volume":"40","author":"Declerck","year":"2018","journal-title":"Clin Ther"},{"key":"key20200714095815_b19-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1634\/theoncologist.2017-0671","article-title":"Global acceptance of biosimilars: Importance of regulatory consistency, education, and trust","volume":"23","author":"Cazap","year":"2018","journal-title":"Oncologist"},{"key":"key20200714095815_b20-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.2146\/ajhp130119","article-title":"Biosimilars: Implications for health-system pharmacists","volume":"70","author":"Lucio","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"key20200714095815_b21-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s11096-017-0523-6","article-title":"Biosimilar uptake by British local formularies: A cross sectional study","volume":"39","author":"Alnahar","year":"2017","journal-title":"Int J Clin Pharm"},{"key":"key20200714095815_b22-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1634\/theoncologist.2017-0126","article-title":"The concept of Biosimilars: From characterization to Evolution-A narrative review","volume":"23","author":"Farhat","year":"2018","journal-title":"Oncologist"},{"key":"key20200714095815_b23-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/conmed-2017-100005","article-title":"Biosimilars: Considerations for clinical practice","volume":"1","author":"Azevedo","year":"2017","journal-title":"Considerations Med"},{"key":"key20200714095815_b24-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40259-018-0262-9","article-title":"Epoetin Biosimilars in the treatment of chemotherapy-induced anemia: 10 years' experience gained","volume":"32","author":"Aapro","year":"2018","journal-title":"BioDrugs"},{"key":"key20200714095815_b25-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2217\/fon-2018-0814","article-title":"Chemotherapy-induced neutropenia\/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study","volume":"15","author":"Ludwig","year":"2019","journal-title":"Future Oncol"},{"key":"key20200714095815_b26-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"91","DOI":"10.5639\/gabij.2013.0202.023","article-title":"Biosimilars in oncology: Current and future perspectives","volume":"2","author":"Aapro","year":"2013","journal-title":"Gen Biosimilars Initiative J (GaBI Journal)"},{"key":"key20200714095815_b27-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1634\/theoncologist.2018-0066","article-title":"Barriers to oncology biosimilars uptake in the United States","volume":"23","author":"Nabhan","year":"2018","journal-title":"Oncologist"},{"key":"key20200714095815_b28-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"3762864","DOI":"10.1155\/2018\/3762864","article-title":"Biosimilars have arrived: Rituximab","volume":"2018","author":"Greenwald","year":"2018","journal-title":"Arthritis"},{"key":"key20200714095815_b29-ol-0-0-11105","unstructured":"European Generic medicines AssociationThe future of pharmaceuticals: Generic medicines enhancing pharmaceutical competition and ensuring healthcare sustainability issues2007http:\/\/198.170.119.137\/doc\/ega_FuturePharmaceuticals.pdfJan122019"},{"key":"key20200714095815_b30-ol-0-0-11105","unstructured":"US FDAFDA approves Truxima as biosimilar to Rituxan for non-Hodgkin's lymphoma2018https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm627035.htmJan152019"},{"key":"key20200714095815_b31-ol-0-0-11105","first-page":"319","article-title":"Development of new formulations of Biologics: Expectations, immunogenicity, and safety for subcutaneous trastuzumab","volume":"32","author":"Pimentel","year":"2018","journal-title":"Pharmaceut Med"},{"key":"key20200714095815_b32-ol-0-0-11105","unstructured":"US FDADrug Approval Package: Ontruzant (trastuzumab-dttb)2019https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761100Orig1s000TOC.cfmJan182019"},{"key":"key20200714095815_b33-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"E168","DOI":"10.3390\/pharmaceutics10040168","article-title":"Concepts and challenges of Biosimilars in breast cancer: The emergence of trastuzumab biosimilars","volume":"10","author":"Uif\u0103lean","year":"2018","journal-title":"Pharmaceutics"},{"key":"key20200714095815_b34-ol-0-0-11105","unstructured":"US FDADrug Approval Package: OGIVRI (trastuzumab-dkst)2017https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761074Orig1s000TOC.cfmDec12017"},{"key":"key20200714095815_b35-ol-0-0-11105","first-page":"91","article-title":"Enhancement of antibody-dependent cell mediated cytotoxicity: A new era in cancer treatment","volume":"4","author":"Rajasekaran","year":"2015","journal-title":"Immunotargets Ther"},{"key":"key20200714095815_b36-ol-0-0-11105","first-page":"9","article-title":"Bevacizumab in Lung Cancer: Impact and Exceptional Cases","author":"Syrigos","year":"2013"},{"key":"key20200714095815_b37-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1586\/14737140.2015.1102063","article-title":"Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer","volume":"15","author":"Grapsa","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20200714095815_b38-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1158\/1078-0432.CCR-18-0566","article-title":"FDA's approval of the first biosimilar to bevacizumab","volume":"15","author":"Casak","year":"2018","journal-title":"Clin Cancer Res"},{"key":"key20200714095815_b39-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jgo.2016.09.006","article-title":"Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study)","volume":"8","author":"Aapro","year":"2017","journal-title":"J Geriatr Oncol"},{"key":"key20200714095815_b40-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000356193","article-title":"Physiology and pharmacology of erythropoietin","volume":"40","author":"Jelkmann","year":"2013","journal-title":"Transfus Med Hemother"},{"key":"key20200714095815_b41-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"E62","DOI":"10.1503\/cmaj.090470","article-title":"Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: A meta-analysis","volume":"180","author":"Tonelli","year":"2009","journal-title":"CMAJ"},{"key":"key20200714095815_b42-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"S2084","DOI":"10.1016\/j.jtho.2017.09.1141","article-title":"P2.01-039 Erythropoiesis-stimulating agents for chemotherapy-induced anaemia in lung cancer: Efficacy, toxicity and effect on survival","volume":"12","author":"Xirou","year":"2017","journal-title":"J Thorac Oncol"},{"key":"key20200714095815_b43-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"968927","DOI":"10.1155\/2015\/968927","article-title":"Epoetin alpha and Epoetin zeta: A comparative study on stimulation of angiogenesis and wound repair in an experimental model of burn injury","volume":"2015","author":"Irrera","year":"2015","journal-title":"Biomed Res Int"},{"key":"key20200714095815_b44-ol-0-0-11105","first-page":"54","article-title":"Biosimilars: Considerations for Payers","volume":"44","author":"Smeeding","year":"2019","journal-title":"PT"},{"key":"key20200714095815_b45-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/CEOR.S12494","article-title":"Biosimilar medicines and cost-effectiveness","volume":"3","author":"Simoens","year":"2011","journal-title":"Clinicoecon Outcomes Res"},{"key":"key20200714095815_b46-ol-0-0-11105","unstructured":"European Generic medicines Association. The future of pharmaceuticalsGeneric medicines enhancing pharmaceutical competition and ensuring healthcare sustainability issues. 2007http:\/\/198.170.119.137\/doc\/ega_FuturePharmaceuticals.pdfFeb12019"},{"key":"key20200714095815_b47-ol-0-0-11105","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2217\/fon.14.43","article-title":"Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: A simulation for the EU G5 countries","volume":"10","author":"Abraham","year":"2014","journal-title":"Future Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T10:05:56Z","timestamp":1594721156000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2019.11105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":47,"URL":"https:\/\/doi.org\/10.3892\/ol.2019.11105","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,15]]}}}